From NGS Data to Scalable Antibody and Nanobody Development Workflows

While NGS has transformed how antibody and nanobody candidates are identified, applying it across development and manufacturing introduces a distinct set of operational and data management challenges. In a previous article, we examined how NGS enables deeper analysis of antibody repertoires and supports more effective candidate selection.  

As programs move beyond discovery, the challenge shifts from generating sequencing data to managing it consistently and translating it into reliable, scalable workflows. Organizations must be able to integrate, analyze, and interpret large NGS datasets in a way that supports development, quality control, and regulatory requirements. Genedata Selector^® supports this transition by enabling standardized, traceable NGS workflows that connect data management, analysis, and reporting. 

Overcoming NGS-Based Challenges  

NGS-based antibody and nanobody discovery generates complex datasets that must be processed, analyzed, and interpreted in a consistent manner. Typical workflows include raw data processing steps such as de-multiplexing, quality control, sequence clustering, and diversity analysis to identify high-specificity binders across repertoires, including those present at low frequency.  

The challenge lies not in sequencing itself, but in translating this data into reproducible and decision-ready outputs. Organizations must manage data integration, standardize analysis pipelines, and ensure consistent interpretation across experiments and teams. Genedata Selector addresses these challenges by enabling structured, in-house NGS workflows that connect sample registration, automated analysis, and reporting. This supports consistent data handling and reduces reliance on fragmented or manual processes across discovery programs. 

While NGS is often associated with repertoire analysis and candidate identification during discovery, its role evolves as antibody and nanobody programs advance. In later development stages, sequencing is used to verify genetic integrity, assess clonal stability, support biosafety testing, and maintain traceable records in regulated environments. Standardized workflows are essential to support these diverse applications and ensure data can be managed consistently throughout the product lifecycle. 

NGS Methods in Antibody and Nanobody Development and Beyond  

Once these challenges are addressed, NGS can be applied across multiple stages of antibody and nanobody development and manufacturing. Beyond discovery, it supports processes from cell line selection to quality control, including sequence verification, contamination detection, and large-scale data analysis.  

High-throughput approaches have expanded the scale at which antibody and nanobody repertoires can be interrogated and translated into development pipelines, reinforcing the importance of capturing diverse candidate pools early in development.¹ 

When supported by standardized workflows, NGS enables consistent and scalable use of sequencing data across the development pipeline. 

Cell Line Development and Clone Selection  

NGS plays a key role in cell line development (CLD) by enabling sequence-level characterization of production clones.² This includes verification of correct transgene integration, assessment of clonal stability across passages, and monitoring of expression consistency. While these insights support clone selection decisions, they complement other critical selection criteria such as productivity, growth characteristics, product quality attributes, and long-term stability. 

Compared with traditional approaches that evaluate a limited number of clones, NGS enables screening of much larger clone panels — often hundreds rather than dozens — providing earlier and more comprehensive insight into clone performance. This supports a more consistent and data-driven selection of optimal production clones. 

Genomic Integrity and Sequence Verification 

Genomic integrity refers to the stability and accuracy of genetic material used in biologics manufacturing. In antibody and nanobody development, NGS supports verification of gene sequences by confirming sequence fidelity, detecting mutations, insertions, or deletions, and validating alignment against reference sequences, as well as assessing host cell genome stability. 

Compared with Sanger sequencing, NGS can provide more comprehensive coverage of integrated sequences and may enable the detection of low-frequency variants that could otherwise remain undetected.³ The sensitivity and reliability of variant detection depend on factors including sequencing depth, library preparation quality, error-correction strategies, and bioinformatics analysis. Standardized and validated workflows are therefore essential to ensure accurate interpretation and consistent results in regulated environments. 

Biosafety Testing and Adventitious Agent Detection 

Biosafety testing is a regulatory requirement in biologics manufacturing to ensure the absence of adventitious agents that could compromise product safety. In line with ICH Q5A guidelines, NGS can support the detection of viral contaminants.⁴ Additionally, NGS can detect a broad range of other contaminants, including bacterial, fungal, and mycoplasma agents, as well as potential cross-contamination from other cell lines.⁵

Traditional approaches show clear limitations: in vivo testing is time-intensive and expensive, while PCR-based assays are restricted to known targets and may fail to detect novel contaminants. By contrast, NGS provides an unbiased, sequencing-based approach that enables broader detection within a single workflow.⁵ Realizing these benefits requires validated laboratory and data analysis workflows to ensure reliable detection and interpretation of sequencing results. Standardized processes, appropriate controls, and traceable data management help distinguish meaningful findings from technical background signals and support regulatory compliance. 

When supported by structured and traceable data management, these capabilities enable earlier risk identification, help prevent production delays, and support regulatory compliance for biosafety and patient safety. 

Process Development and Manufacturing Quality Control 

As antibody and nanobody programs progress into development and manufacturing, NGS generates large volumes of data that must be managed within robust and validated workflows. Manufacturing-grade environments require end-to-end sample tracking, automated and validated analysis pipelines, and structured results management, including trending and reporting to support regulatory submissions. 

Ensuring data integrity, security, and traceability is critical. This includes audit capabilities, version control, and change management to maintain compliance in regulated environments. Integration with laboratory systems, including laboratory information management systems (LIMS) and manufacturing systems, further supports consistent data flow across processes.  

By establishing standardized and scalable data workflows, organizations can apply NGS more reliably in manufacturing environments and enable consistent, data-driven decision-making across development and quality control. 

Conclusion: Enabling Scalable and Compliant NGS Workflows 

While NGS provides critical insights across antibody and nanobody development, its value depends on the ability to manage complex data consistently across development processes. From cell line development and sequence verification to biosafety testing and manufacturing quality control, NGS supports more reliable decision-making when implemented within structured workflows. 

By establishing standardized analysis, traceable data management, and scalable deployment, Genedata Selector supports the integration of NGS across development and manufacturing environments. This allows organizations to translate sequencing data into consistent, compliant workflows. 

Learn more about how Genedata supports scalable, compliant NGS workflows across antibody and nanobody development and manufacturing.